Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study

BMC Cancer

Wei-Wei Ouyang¹  Sheng-Fa Su¹  Yin-Xiang Hu¹  Bing Lu¹  Zhu Ma¹  Qing-Song Li¹  Hui-Qin Li¹  Yi-Chao Geng¹ 

[1] Teaching and Research Section of Oncology, Guiyang Medical College, Guizhou, Guiyang, China

关键词: Response;    Dose;    Thoracic three-dimensional radiotherapy;    Concurrent chemoradiotherapy;    Stage IV;    Non-small cell lung cancer;   

Others  :  856927
DOI  :  10.1186/1471-2407-14-491

 received in 2014-02-05, accepted in 2014-07-04,  发布年份 2014

【 摘 要 】

Background

The objective of this study was to evaluate the radiation dose and response in terms of local-regional progression-free survival (LRPFS) and overall survival (OS) of patients with stage IV non-small cell lung cancer (NSCLC) undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy.

Methods

In all, we enrolled 201 patients with stage IV NSCLC in this study and analyzed OS in 159 patients and LRPFS in 120.

Results

The 1-, 2-, 3-, and 5-year OS rates were 46.2%, 19.5%, 11.7%, and 5.8%, respectively, the median survival time being 12 months. The median survival times in differential treatment response of primary tumors were 19 of complete response, 13 of partial response, 8 of stable disease, and 6 months of progressive disease, respectively (P = 0.000). The 1-, 2-, 3-, and 5-year LRPFS rates of patients undergoing four to five cycles with doses ≥63 Gy and <63 Gy were 77.4% and 32.6%, 36.2% and 21.7%, 27.2% and 0, and 15.9% and 0, respectively (P = 0.002). According to multivariate analyses, four to five cycles of chemotherapy, gross tumor volume <175.00 cm³ and post-treatment Karnofsky Performance Status score stable or increased by at least 10 units were independent prognostic factors for better OS (P = 0.035, P = 0.008, and P = 0.000, respectively). Radiation dose to the primary tumor ≥63 Gy resulted in better OS (P = 0.057) and LRPFS (P = 0.051), both findings being of borderline significance.

Conclusions

Treatment of IV NSCLC with joint administration of four to five cycles of chemotherapy and three-dimensional radiotherapy may prolong survival, particularly in patients receiving ≥63 Gy radiotherapy, with gross tumor volume <175.00 cm³ and post-treatment Karnofsky Performance Status score not lower than pretreatment values.

【 授权许可】

   
2014 Ouyang et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(2):92-98.
• [2]Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21(16):3016-3024.
• [3]Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
• [4]Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
• [5]Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
• [6]Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T: Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013, 24(1):54-59.
• [7]Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L, Tonato M: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20(21):4285-4291.
• [8]Wagner H Jr: Just enough palliation: radiation dose and outcome in patients with non-small-cell lung cancer. J Clin Oncol 2008, 26(24):3920-3922.
• [9]Fang LC, Komaki R, Allen P, Guerrero T, Mohan R, Cox JD: Comparison for patients with medically inoperable stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 2006, 66(1):108-116.
• [10]Bradley JD, Paulus R, Komaki R, Masters GA, Forster K, Schild SE, Bogart J, Garces YI, Narayan S, Kavadi V, Nedzi LA, Michalski JM, Johnson D, Macrae RM, Curran WJ, Choy H: A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617. J Clin Oncol 2013, 31(15Suppl):7501. 2013 ASCO Annual Meeting Abstracts
• [11]Kim DW, Shyr Y, Chen H, Akerley W, Johnson DH, Choy H: Response to combined modality therapy correlates with survival in locally non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2005, 63(4):1029-1036.
• [12]Kong FM, Ten Haken RK, Schipper MJ, Sullivan MA, Chen M, Lopez C, Kalemkerian GP, Hayman JA: High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005, 63(2):324-333.
• [13]Su SF, Hu YX, Ouyang WW, Lu B, Ma Z, Li QS, Li HQ, Geng YC: Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small cell lung cancer: results of a prospective single-center study. BMC Cancer 2013, 13:474.
• [14]Lopez Guerra JL, Gomez D, Zhuang Y, Hong DS, Heymach JV, Swisher SG, Lin SH, Komaki R, Cox JD, Liao Z: Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys 2012, 84(1):e61-e67.
• [15]Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551.
• [16]Manegold C: Chemotherapy for advanced non-small cell lung cancer: standards. Lung Cancer 2001, 34(Suppl 2):S165-S170.
• [17]Spigel DR, Greco FA: Chemotherapy in metastatic and locally advanced non-small cell lung cancer. Semin Surg Oncol 2003, 21(2):98-110.
• [18]Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, Weichselbaum RR: Analysis of disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol 2004, 25(6):1677-1683.
• [19]Higginson DS, Chen RC, Tracton G, Morris DE, Halle J, Rosenman JG, Stefanescu M, Pham E, Socinski MA, Marks LB: The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys 2012, 84(3):e385-e392.
• [20]Fairchild A, Goh P, Sinclair E, Barnes EA, Ghosh S, Danjoux C, Barbera L, Tsao M, Chow E: Has the pattern of practice in the prescription of radiotherapy for the palliation of thoracic symptoms changed between 1999 and 2006 at the rapid response radiotherapy program? Int J Radiat Oncol Biol Phys 2008, 70(3):693-700.
• [21]Sundstrøm S, Bremnes R, Aasebø U, Aamdal S, Hatlevoll R, Brunsvig P, Johannessen DC, Klepp O, Fayers PM, Kaasa S: Hypofractionated palliative radiotherapy(17 Gy per two fractions)in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III Trial. J Clin Oncol 2004, 22(5):801-810.
• [22]Flannery TW, Suntharalingam M, Regine WF, Chin LS, Krasna MJ, Shehata MK, Edelman MJ, Kremer M, Patchell RA, Kwok Y: Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys 2008, 72(1):19-23.
• [23]Kramer GW, Wanders SL, Noordijk EM, Vonk EJ, van Houwelingen HC, van den Hout WB, Geskus RB, Scholten M, Leer JW: Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for non-small cell lung cancer. J Clin Oncol 2005, 23(13):2962-2970.
• [24]Fairchild A, Harris K, Barnes E, Wong R, Lutz S, Bezjak A, Cheung P, Chow E: Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol 2008, 26(24):4001-4011.
• [25]Rodrigues G, Videtic GM, Sur R, Bezjak A, Bradley J, Hahn CA, Langer C, Miller KL, Moeller BJ, Rosenzweig K, Movsas B: Palliative thoracic radiotherapy in lung cancer: an American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol 2011, 1(2):60-71.
• [26]Azzoli CG, Temin S, Aliff T, Baker S Jr, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G: 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011, 29(28):3825-3831.